Company intelligence / Profile preview

PHAXIAM Therapeutics

Lyon, Auvergne-Rhône-Alpes, Franceerytech.com ↗

Ownership: Private
Employees: ~125
Development stage: Other

Overview

ERYTECH Pharma has developed a pipeline of red blood cell-based therapeutics using its proprietary ERYCAPS® platform. Its lead candidate, eryaspase/GRASPA®, has shown positive efficacy and safety results in relapsed/refractory ALL and has also been evaluated in AML and metastatic pancreatic cancer. The company’s approach aims to deprive tumor cells of essential nutrients by enzymatic depletion while reducing toxicity compared to conventional therapies. Orphan drug designations have been granted by both EMA and FDA for several indications.

Therapeutic areas: OncologyHematology
Modalities: Enzyme therapies encapsulated in red blood cellsRed blood cell-based therapeutics
Industry: Biotech

Drug pipeline

11 assets

eryaspase

10 more assets in the full pipeline.

Partnerships

Orphan Europe / Recordati Group – licensing/distribution agreement for EuropeTEVA Pharmaceutical Industries Ltd. – licensing/distribution agreement for Israel

Beyond the preview

Go deeper on PHAXIAM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHAXIAM Therapeutics.